Patients with a range of rheumatic diseases are at increased risk of cardiovascular disorders towards a re-evaluation of the European League against Rheumatism (EULAR)’s recommenda... ανά Conrad, N, McInnes, IB, Mcmurray, JJV, Sattar, N

Clinical applications of machine learning algorithms: beyond the black box. ανά Watson, DS, Krutzinna, J, Bruce, IN, Griffiths, CE, McInnes, IB, Barnes, MR, Floridi, L

Gout and incidence of 12 cardiovascular diseases: a case–control study including 152 663 individuals with gout and 709 981 matched controls ανά Ferguson, LD, Molenberghs, G, Verbeke, G, Rahimi, K, Rao, S, McInnes, IB, McMurray, JJV, Sattar, N, Conrad, N

Baricitinib, tofacitinib, upadacitinib, filgotinib, and cytokine signaling in human leukocyte subpopulations: an updated ex-vivo comparison ανά McInnes, IB, Rocha, G, Higgs, R, Dairaghi, D, Wehrman, T, Wang, E, Zhang, X, Terres, JR, Rooney, T, Taylor, PC

Patient and researcher perspectives on facilitating patient and public involvement in rheumatology research ανά Pollock, J, Raza, K, Pratt, AG, Hanson, H, Siebert, S, Filer, A, Isaacs, JD, Buckley, CD, McInnes, IB, Falahee, M

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase... ανά Coates, LC, Rahman, P, Mease, PJ, Shawi, M, Rampakakis, E, Kollmeier, AP, Xu, XL, Chakravarty, SD, McInnes, IB, Tam, L-S

Single cell and spatial transcriptomics in human tendon disease indicate dysregulated immune homeostasis ανά Akbar, M, MacDonald, L, Crowe, LAN, Carlberg, K, Kurowska-Stolarska, M, Ståhl, PL, Snelling, SJB, McInnes, IB, Millar, NL

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phas... ανά Coates, L, Gossec, L, Theander, E, Bergmans, P, Neuhold, M, Karyekar, CS, Shawi, M, Noel, W, Schett, G, McInnes, IB

Effect of secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients ανά Orbai, A-M, McInnes, IB, Coates, LC, Husni, ME, Gladman, DD, Gossec, L, Pricop, L, Chambenoit, O, Meng, X, Mease, PJ

Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis ανά Pournara, E, Kormaksson, M, Nash, P, Ritchlin, CT, Kirkham, BW, Ligozio, G, Pricop, L, Ogdie, A, Coates, LC, Schett, G, McInnes, IB

IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy ανά Krueger, JG, Eyerich, K, Kuchroo, VK, Ritchlin, CT, Abreu, MT, Elloso, MM, Fourie, A, Fakharzadeh, S, Sherlock, JP, Yang, Y, Cua, DJ, McInnes, IB

Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in t... ανά Conrad, N, Misra, S, Verbakel, JY, Verbeke, G, Molenberghs, G, Taylor, PN, Mason, J, Sattar, N, McMurray, JJV, McInnes, IB, Khunti, K, Cambridge, G

The impact of the presence of autoantibodies against citrullinated, carbamylated and acetylated peptides on radiographic progression in patients with new onset rheumatoid arthritis... ανά Nijjar, JS, Morton, FR, Bang, H, van der Heijde, D, Gilmour, A, Paterson, C, McInnes, IB, Raza, K, Buckley, C, Scottish Early Rheumatoid Arthritis Inception Cohort Investigators

Safety of guselkumab with and without prior TNF-α inhibitor treatment: pooled results across four studies in patients with psoriatic arthritis ανά Rahman, P, Boehncke, W-H, Mease, PJ, Gottlieb, AB, McInnes, IB, Shawi, M, Wang, Y, Sheng, S, Kollmeier, AP, Theander, E, Yu, J, Leibowitz, E, Marrache, AM, Coates, LC

Safety and efficacy of bimekizumab in patients with psoriatic arthritis: 2-year results from two phase 3 studies ανά Mease, PJ, Merola, JF, Tanaka, Y, Gossec, L, McInnes, IB, Ritchlin, CT, Landewé, RBM, Asahina, A, Ink, B, Heinrichs, A, Bajracharya, R, Shende, V, Coarse, J, Coates, LC

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase 3, randomised, placebo controlled, active... ανά Ritchlin, CT, Coates, LC, McInnes, IB, Mease, PJ, Merola, JF, Tanaka, Y, Asahina, A, Gossec, L, Gottlieb, AB, Warren, RB, Ink, B, Bajracharya, R, Shende, V, Coarse, J, Landewé, R

Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies ανά Taylor, PC, Kremer, J, Emery, P, Zuckerman, S, Ruotolo, G, Zhong, J, Chen, L, Witt, S, Saifan, C, Kurzawa, M, Otvos, JD, Connelly, MA, Macias, W, Schlichting, DE, Rooney, T, de Bono, S, McInnes, IB

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL) ανά McInnes, IB, Asahina, A, Coates, LC, Landewé, R, Merola, JF, Ritchlin, CT, Tanaka, Y, Gossec, L, Gottlieb, AB, Warren, RB, Ink, B, Assudani, D, Bajracharya, R, Shende, V, Coarse, J, Mease, PJ

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III... ανά Coates, LC, Landewé, R, McInnes, IB, Mease, PJ, Ritchlin, CT, Tanaka, Y, Asahina, A, Behrens, F, Gladman, DD, Gosse, L, Orbai, A-M, Gottlieb, AB, Warren, RB, Ink, B, Bajracharya, R, Shende, V, Coarse, J, Merola, JF

Bimekizumab in patients with active psoriatic arthritis and prior inadequate response or intolerance to tumour necrosis factor inhibitors: a randomised, double-blind, placebo-contr... ανά Merola, JF, Landewé, R, McInnes, IB, Mease, PJ, Ritchlin, CT, Tanaka, Y, Asahina, A, Behrens, F, Gladman, DD, Gossec, L, Gottlieb, AB, Thaçi, D, Warren, RB, Ink, B, Assudani, D, Bajracharya, R, Shende, V, Coarse, J, Coates, LC